GSK just scored a big win: their experimental drug for small-cell lung cancer got Orphan Drug status from the FDA. That means it’s showing promise for a super tough-to-treat cancer, and could get fast-tracked perks like tax breaks and market exclusivity. Early trial results look hopeful for patients who usually have very few options. Fingers crossed this could be a real game-changer for those fighting this aggressive disease! #Health #BodyHealth #LungCancer